Abstract
Infertility continues to be a common medical problem with significant societal repercussions and psychological and economic effects on families' lives. Hysterosalpingography (HSG) is the preferred method in clinical practice for evaluating the uterine cavity and tubal patency. Our study aims to present a comprehensive perspective on the importance of the HSG procedure in the evaluation of infertile patients, starting with the recommendation of the HSG procedure to the patient, the application of the procedure, and the evaluation of the patient's post-procedure process. This is a prospective evaluation of 323 women who underwent HSG at Kafkas University between 2021-2022. The type and duration of infertility in patients, the source from which the patient received the recommendation for HSG, visual pain score for evaluating pain during the HSG procedure, HSG results, patients' perspectives on the procedure's contribution to the treatment processes, their immediate post-procedure pain, and their pregnancy status within 6 months after the procedure were evaluated. 72.1% of patients had primary, and 27.8% had secondary infertility. 82% of HSG results were reported as normal. Among primary infertility, uterine pathologies were detected in 62.5%. In secondary infertile patients, tubal pathology was detected in 88.4%. There is a statistically significant difference between the infertility types of patients with normal HSG results and those without (p=0.001). There was also a difference between the results of HSG and follow-up types (p<0.001). A statistical difference was also found between the HSG result and the patients' conception status within 6 months after the procedure (p<0.001). When it comes to the cost of the HSG procedure for infertility, as well as potential pain, radiation exposure, and rare allergic reactions to the contrast material, it is important to choose the appropriate circumstances for this procedure. In order to avoid unnecessary interventional procedures, it would be beneficial to discuss the recommendation of HSG for primary infertile patients under 28.5 years of age. Further research is required in this regard. Since tubal factors are most common among secondary infertile women, this group of patients is more likely to benefit from HSG in the evaluation.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European review for medical and pharmacological sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.